Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$42.03 - $53.55 $757,212 - $964,756
18,016 Added 143.84%
30,541 $1.32 Million
Q4 2023

Feb 14, 2024

SELL
$43.39 - $51.63 $85,174 - $101,349
-1,963 Reduced 13.55%
12,525 $633,000
Q3 2023

Nov 22, 2023

BUY
$38.5 - $47.13 $557,788 - $682,819
14,488 New
14,488 $657,000
Q3 2022

Nov 14, 2022

SELL
$36.54 - $48.66 $266,595 - $355,023
-7,296 Reduced 11.96%
53,717 $2.38 Million
Q2 2022

Aug 15, 2022

BUY
$31.71 - $43.0 $1.3 Million - $1.76 Million
40,913 Added 203.55%
61,013 $2.26 Million
Q1 2022

May 16, 2022

BUY
$29.88 - $37.04 $397,284 - $492,483
13,296 Added 195.41%
20,100 $744,000
Q4 2021

Feb 14, 2022

BUY
$25.61 - $35.1 $174,250 - $238,820
6,804 New
6,804 $207,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $4.64B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.